Omeros reported a net loss of $23.5 million, or $0.48 per share, in the fourth quarter of 2018 compared with a net loss of $16.6 million, or $0.34 per share, in 2017’s fourth quarter, according to a press release.
The company’s full year financial results included a net loss of $126.8 million, or $2.61 per share, compared with a net loss of $53.5 million, or $1.17 per share, in 2017.
Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution) revenues increased from $13.8 million to $22 million for the quarter and (Read more...)
Uncategorized